AstraZeneca investors press for talks after it spurns Pfizer again
British pharma giant rejects increased £50-a-share offer and refuses to meet its rival
Major investors in the pharmaceuticals giant AstraZeneca have urged the company to start negotiating with its US rival Pfizer after it rejected a sweetened £63bn takeover bid.
Although the assurances on investment helped to soothe political concerns over the £50-per-share bid, the AstraZeneca board yesterday said it had “no hesitation” in rejecting the offer, up 7 per cent from the original £46.61 move, and declared it would not even engage in talks.
AstraZeneca’s decision came after a hastily convened board meeting in London yesterday. The British company said too much of Pfizer’s offer consisted of shares rather than cash, and criticised the fact that the Viagra maker’s rationale for the deal was based upon tax savings. However, one top five shareholder told The Independent: “This is a serious enough offer for AstraZeneca to sit down and talk. We’re disappointed with the rejection but do agree that the bid is too low – the price needs to be higher.”
Another investor said: “Yes, the bid is too low but the rejection was too swift. The first obligation of the board is to shareholders. There should have been more of a discussion before such a fundamental decision was made.”
The influential Institute of Directors also warned MPs against intervening on political grounds, insisting that the takeovers are “primarily a matter for boards and shareholders to determine, not government”.
Robin Barker, the director of corporate governance at the IoD, added: “The board of AstraZeneca has so far rejected the bid, and they should continue to be sceptical about whether a tax-driven strategy makes the takeover in the long-term interest of the company.”
Read more: The town that Pfizer built up – and knocked down
Pfizer AstraZeneca takeover: Insider warns that acquisition could be ‘devastating’ for research
Sources close to the negotiations now expect Pfizer to come back with a higher offer as soon as next week. AstraZeneca is expected to meet with key investors over the next few days.
Pfizer’s chief executive Ian Read had attempted to soothe political concerns about the impact on Britain’s skilled workforce in a letter to the Prime Minister.
He also piled the pressure on Astra’s board to set up discussions, with the clipped comment: “Although we would have liked more time to meet privately to discuss our latest proposal, I believe that our revised terms are sufficient for you to agree to meet with us.”
Mr Read told David Cameron of the virtues of the “golden triangle”of Oxford, Cambridge and London, and pledged to complete AstraZeneca’s planned £300m Cambridge campus as well as employing at least a fifth of the combined company’s total research and development workforce in the UK. Pfizer spent only about 10 per cent of its revenues last year on research and development versus Astra’s 16 per cent spend, and its record of takeovers is one of heavy job cuts.
Yesterday, Pfizer committed itself to offering at least two AstraZeneca board members a place on the new company’s non-executive committee. It also agreed to hold board meetings in the UK.
In the latest bid, the cash element has been raised to 32 per cent from 30 per cent. Astra shares closed down 7p at 4,808p.
- 1 Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
- 2 Pictures show young Palestinian girl biting Israeli soldier trying to detain boy during West Bank protests
- 3 Watch the Supermoon live: How to see the brightest Moon of the year tonight
- 4 Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
- 5 Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
Celebrity Big Brother 2015: Tila Tequila kicked off show after 'describing Hitler as a good man'
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Stock up on canned food for stock market crash, warns former Gordon Brown adviser
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...